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Abstract
Background The recent update of the European Union’s (EU) regulation on public procurement has created new opportu-
nity for progress in the purchasing of medical devices by shifting towards focus on value from one purely on price. Patient-
reported outcome measures (PROMs) may serve as additional tools for manufacturers to demonstrate value beyond traditional 
metrics of safety and performance and to differentiate their products in a market of increasing competition. The aim of our 
study was to investigate the extent to which PROMs are included in registered device studies in the EU and interpret the 
results in the context of the purchasing of medical devices.
Methods Twelve device groups were searched in clinical trial registries to determine the frequency distribution of PROMs 
in related studies.
Results Results indicate that clinical studies of the selected device categories are done predominately in the western EU 
nations and are increasingly including PROMs. In the United Kingdom 121 (65%) study, out of 186 included PROMs, and in 
Germany, 92 (52%) out of 178 between 1998 and 2018. Few device studies were done in the Central and Eastern European 
region, and out of 76 studies 27 (35%) included PROMs. Since there is no requirement to include PROMs in device studies 
for regulatory purposes, it seems probable that their increasing use is driven by competitive market pressures.
Conclusion The trend of increasing use of PROMs might be driven by the demand of purchasers to demonstrate value of 
devices, but is manifested at different levels in various regions of the EU.
Keywords Medical device · Patient-reported outcome · Value-based purchasing · Europe
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Introduction
The role of medical devices has dramatically increased in 
the provision of healthcare services in the last few decades. 
Access to state-of-the-art devices allows the diagnosis and 
treatment of diseases that have not been detectable and/
or treatable earlier. Medical device manufacturers need to 
differentiate their products on a highly competitive market. 
The payers, including hospitals and health insurance entities, 
make cost-conscious purchasing decisions to maximize the 
effectiveness of healthcare services. Device manufacturers 
need to demonstrate product value beyond the traditional 
measures of clinical safety and efficacy. Patient-reported 
outcomes (PROs) may be suitable for this purpose [1].
PRO measures (PROMs) the perception of patients on 
their own experience and outcomes, including health-
related quality of life, in response to an intervention. 
These measures can complement other clinical and physi-
ological information or, in some cases, substitute for them 
[2]. In addition, PROMs may allow gathering important 
information on health status that is not detectable by other 
measures [3]. For instance, in orthopedic studies, PROMs 
are commonly used to quantify functional mobility, pain 
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levels, and disability [4]. Thus, PROMs can serve as com-
ponents in composite endpoints for clinical studies [5].
In the United States between 2009 and 2015, a > 500% 
increase was observed in the number of device studies 
that included PROMs [6]. It was also observed that the 
PROMs were often based on subjectively collected data 
with the potential for unreliable measurement [7]. The US 
Food and Drug Administration (FDA) launched the Medi-
cal Device Development Tool Program in 2017 to assist 
study sponsors to incorporate valid PROMs into device 
clinical trials [8].
Different stakeholders have different perspectives on 
PROMs. Regulatory agencies, like FDA in the United 
States and Notified Bodies in the European Union, may use 
PROMs to support or deny the claim of the manufacturer 
concerning the safety or efficiency of a device. Payers and 
providers may use PROMs to compare alternative devices, 
including new devices with modest design modification in 
comparison with previous versions, for purposes of both 
purchasing and clinical implementation [9, 10].
There is an ethical obligation to disclose the findings of 
clinical trials. Only half of the studies of high-risk medical 
devices are published and there often are discrepancies in 
important study features between the summary provided 
to the regulatory agencies and the eventual publication in 
peer-reviewed journals [11, 12]. The extent of publica-
tion bias is measurable in those countries, where clinical 
trial registries provide information on the device studies 
in accordance with the requirements of the International 
Committee of Medical Journal Editors (IMCJE) [13]. The 
European Clinical Trial Register, however, does not pro-
vide information on clinical trials for medical devices [14]. 
Although every member states of the European Union 
(EU) require the registration of device clinical studies 
before commencing studies, there are considerable dif-
ferences in the publicly available information on study 
features. The German Clinical Trials Register (DRKS), 
the United Kingdom’s ISRCTN Registry, ClinicalTrials.
gov, and the International Clinical Trials Registry Plat-
form (ICTRP) of the World Health Organization make 
important details available for the public. In contrast, 
most of the member states of the EU do not have clinical 
trial registries with that level of transparency. Data from 
these registries may provide more accurate estimates of 
the prevalence of PRO measures used in clinical trials for 
medical devices than a review of peer-reviewed journals.
The aim of this paper is to show the trend in the use of 
PROMs for registered device studies in the EU and inter-
pret the results in the context of the purchasing of medi-
cal devices. Owing to the diversity of medical devices, our 
study was limited to twelve specific device categories and 
we attempted to extrapolate to the overall role of PROMs in 
the procurement of medical devices in the EU.
Methods
Selection of medical devices
Twelve implantable and high-risk (class IIb & III) medical 
device therapeutic groups were selected for investigation 
according to the risk-based classification system of the 
Medical Device Regulation 2017/745. Six out of the 12 
were class IIb devices, including dental implants, periph-
eral venous catheters, intramedullary nails, orthopedic 
plates, spinal fusion devices, and contact lens solutions. 
The other six devices belong to class III risk category, 
including cardiac pacemakers, bone grafts, hip implants, 
central venous catheters, intraocular lens, and absorbable 
sutures. Most of the selected device groups are intended 
for cardiologic and orthopedic interventions that are 
among the most expensive and risky service lines [15]. 
The other device groups were selected based on the large 
populations using them.
Search of clinical trial databases
The German Clinical Trials Register, the United King-
dom’s ISRCTN Registry, ClinicalTrials.gov, and the Inter-
national Clinical Trials Registry Platform of the World 
Health Organization were searched manually to identify 
clinical trials of the 12 categories of medical devices. 
The search was restricted to studies that have been con-
ducted in the EU. The database search was carried until 
December 31, 2018. Interventional and observational 
studies were searched without limitation on time period. 
Completed, active, terminated, and studies in recruiting 
phase were included in the search. The search strategy 
was constructed using a single set of keywords, such terms 
identifying medical device categories: dental implant OR 
hip implant OR orthopedic plate OR cardiac pacemaker 
OR intramedullary nail OR absorbable suture OR spinal 
fusion device OR bone graft OR contact lens solution OR 
intra-ocular lens OR peripheral venous catheter OR central 
venous catheter. No further limitation was applied. All 
search hits were assessed without exclusion. Duplications 
were excluded by marking each hit in the databases after 
the review of the belonging synopsis. Studies were taken 
into consideration for further analysis if they disclosed 
clear information on (i) the objective of the study, (ii) test 
device, (iii) the experimental design, (iv) endpoints, and 
(v) the sponsor. Studies were excluded from further analy-
sis if they were designed to assess the efficiency/effective-
ness of surgical or treatment approaches in general, or if 
the applied device was not clearly identifiable. The qual-
ity of the published synopses was not evaluated in terms 
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of comprehensiveness and accuracy. All PROMs used in 
device studies either as primary or secondary outcomes 
were recorded for each device categories along with the 
starting date and locations of the studies.
Data analysis
Clinical studies of medical devices were counted for each 
year until 2018, and the distribution of the studies was deter-
mined between the member states of the EU. Multicenter 
studies were taken into account in each country, where they 
had investigational site, as if they were local, single-center 
studies. The proportion of the most often used health-related 
quality-of-life (HRQoL) and disease-specific outcome meas-
ures was determined for all selected device groups. The 
number and proportion of studies that included PROMs were 
measured, as were trends over time.
Results
The first device studies were registered in 1998 in the 
searched databases. Altogether, 1,828 publicly available 
synopses of clinical studies were reviewed in relation to the 
selected device categories concerning the time period from 
1998 to 2018. Of these, 1073 were excluded from further 
analysis, because their objective was not the investigation 
of the clinical safety or performance of devices but, rather, 
that of concomitant interventions. Of the remaining 755 
device studies, 381 (50%) included PROMs as primary or 
secondary endpoints, implying single and multicenter stud-
ies (Fig. 1).
Our results show that an increasing proportion of medical 
device studies include PROMs in the EU (Fig. 2). Almost all 
(94%) of these studies were conducted in Western European 
countries, with the United Kingdom (24%) and Germany 
(18%) standing out. Only 6% of the studies were performed 
in the Central Eastern European (CEE) region, the major-
ity of them in Poland and Hungary, respectively. PROMs 
were not included at all in device studies in Latvia, Lithu-
ania, and Estonia (Table 1). Out of the 381 device, studies 
that included PROMs 48 (12.6%) were multicenter studies, 
i.e., 14 (12.6%) for hip implants, 4 (10.5%) for bone grafts, 
3 (7.14%) for cardiac pacemakers, 6 (17.1%) for intraocu-
lar lens, 11 (27.5%) for spinal fusion devices, 5 (17.8) for 
intramedullary nails, and 5 (10.4%) for orthopedic plates.
Total number of device studies 
(n=1828)
Studies excluded because their objective was the investigation of 
concomitant treatments
(n=1073)
Studies with the objective to investigate the safety and 
performance of devices
(n=755)
Studies that included PROM as endpoint
(n=381)
Fig. 1  Methodology and result of clinical trial registry search
Fig. 2  Increasing trend in the quantity of clinical studies of medical devices that included PROM as primary or secondary endpoints
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Table 1  Distribution of studies 
of selected device categories 
between the EU member states
Concerning the CEE region, 27 (35%) device studies included some kind of PROMs. Most of the device 
studies are organized in Poland and in Hungary, respectively. There is no data on device related clinical 
studies from Bulgaria. CEE region implies Poland, Czech Republic, Slovakia, Hungary, Slovenia, Croatia, 
Romania, Bulgaria and the Baltic states
EU member states Total number of studies Number of studies that 
included PRO measures
Proportion of studies 
included PROM (%)
United Kingdom 186 (18%) 121 (24%) 65
Germany 178 (17%) 92 (18%) 52
France 108 (10%) 42 (10%) 39
Italy 98 (9.5%) 16 (3%) 16
Spain 79 (7.7%) 39 (8%) 49
The Netherlands 65 (6.3%) 28 (5%) 43
Belgium 57 (5.5%) 28 (5%) 49
Austria 56 (5.5%) 13 (2.5%) 23
Denmark 54 (5.2%) 27 (5%) 50
Sweden 52 (5%) 27 (5%) 52
Switzerland 52 (5%) 13 (2.5%) 25
Norway 28 (2.7%) 25 (5%) 89
Poland 23 (2.2% 9 (2%) 39
Finland 18 (1.7%) 5 (1%) 28
Hungary 18 (1.7%) 4 (0.8%) 22
Czech Republic 14 (1.4%) 5 (1%) 36
Portugal 14 (1.4%) 5 (1%) 36
Slovakia 7 (0.7%) 4 (0.8%) 57
Greece 4 (0.4%) 3 (0.6%) 75
Ireland 4 (0.4%) 2 (0.4%) 50
Latvia 4 (0.4%) 0 (0%) 0
Romania 4 (0.4%) 3 (0.6%) 75
Lithuania 3 (0.3%) 0 (0%) 0
Croatia 1 (0.1%) 1 (0.2%) 100
Estonia 1 (0.1%) 0 (0%) 0
Slovenia 1 (0.1%) 1 (0.2%) 100
Table 2  Frequency distribution 
of device studies with and 
without PROMs
PROMs were included in orthopedic and trauma device studies more often than in other device categories
Device categories Total number of 
studies
Number of studies 
included PROM
Proportion of studies 
included PROM (%)
Absorbable sutures 55 12 22
Bone grafts 228 33 15
Cardiac pacemakers 339 50 15
Central venous catheters 182 10 5
Contact lens solutions 40 9 22
Dental implants 202 20 10
Hip implants 236 103 44
Intramedullary nails 61 26 43
Intraocular lens 218 33 15
Orthopedic plates 95 46 48
Peripheral venous catheters 58 33 57
Spinal fusion devices 114 36 32
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Concerning the selected device categories, most of the 
trauma and orthopedic device studies included PROMs, 
whereas they were used significantly less frequently in other 
device studies (Table 2). PROMs were included in 46 (48%) 
studies of orthopedic plates, in 103 (44%) hip implant, 36 
(32%) spinal fusion, 26 (43%) intramedullary nail, 12 (22%) 
absorbable suture, 33 (15%) bone graft, 33 (15%) intraocular 
lens, 9 (22%) contact lens solution, 20 (10%) dental implant, 
50 (15%) cardiac pacemaker, 33 (57%) peripheral venous 
catheter, and in 10 (5%) central venous catheter studies.
The frequency of general HRQoL measures in device 
studies is shown in Table 3. General HRQoL measures, such 
as EQ-5D (29.7%), Short Form 36 (SF-36) (6.6%), Short 
Form 12 (SF-12) (2.6%), and patient satisfaction index (PSI) 
(1%) turned up in the reviewed device studies. Pain associ-
ated with interventions was often measured on visual ana-
logue scale (VAS) (19.7%), but numeric-rating scale (NRS) 
(0.3%) appeared in our search, as well (Table 3). In the CEE 
region, 76 device studies were carried out and 27 (35%) of 
them included PROMs. Out of the 27, VAS was applied in 
12 studies (44%), EQ-5D in 10 studies (32%), SF-36 in 7 
studies (26%), ODI in 6 studies (22%), SF-08 in 2 studies 
(7%), HHS in 2 studies (7%), OHS in 1 study (4%), and NRS 
in 1 study (4%).
Disease-specific PROMs showed a large diversity in 
trauma and orthopedic device studies. Minnesota Living 
with Heart Failure (MLWHF) was the only cardiac disease-
specific PRO instrument that turned up in conjunction with 
cardiac pacemaker studies (Table 4). Regarding the selected 
orthopedic and trauma devices, osteoarthritis (WOMAC and 
HOOS), pain, and function related to total hip arthroplasty 
(HOS), functionality of upper extremities (DASH), dis-
ability (ODI), and pain in the wrist joint (PWRE) measures 
were most often applied. Harris Hip Score (HHS), which 
is a composite measure of clinician-, and patient-reported 
outcomes that encompasses subscales for the function 
and pain in relation to the hip disorders, also was used 
frequently. For ophthalmological devices, vision-targeted 
health status (VFQ25), visual function index (VF-14), and 
the contact lens user experience (CLUE) were used most 
frequently. Concerning dental implants, oral health impact 
profile (OHIP) has been applied to measure the oral health-
related quality of life of patient after dental implant surgery 
(Table 4). In a number of cases, the intention to apply a 
PROM was clearly indicated in the synopses of the device 
studies, but the actual instrument was not defined (data not 
shown).
Two-thirds (68%) of the studies that included PROMs 
were sponsored by research organizations or by govern-
ment, with the remainder sponsored by industry. In 14% 
of the research organization-sponsored studies, the device 
manufacturer participated either as a collaborator or as the 
funding party.
Discussion
There is a strong trend towards increased use of PROMs in 
clinical studies of medical devices, most of which are con-
ducted in the Western European region. General HRQoL 
measures turned up in each device category, though their 
use is quite rare compared to pharmaceutical studies [10]. 
Disease-specific instruments were used most frequently 
in orthopedic and trauma related studies, providing more 
accurate and detailed information about patient’s experi-
ence. In terms of sponsorship, the distribution of studies 
that included PROMs was similar between research organi-
zations and industry.
The increasing use of PROMs in device studies in the EU 
is comparable to that in the United States. The studies in 
the United States were all linked to label claims granted by 
the FDA [6]. In contrast, the industry-sponsored studies in 
our research might not be construed as pilot or pivotal stud-
ies to support the Conformité européenne (CE) marking of 
products. Most of the reviewed studies had no publicly avail-
able results in the searched clinical trial registries, perhaps 
Table 3  Frequency of general 
HRQoL measures in device 
studies
General HRQoL measures are still relatively rarely used (12.5%) in device studies. In studies that included 
PROMs general HRQoL measures were applied in 59.9%. Out of the six identified measures, EQ-5D is the 
dominant followed by VAS, while the frequency of other measures is far behind these two
General HRQoL meas-
ures
Frequency in relation to the number of stud-
ies included PROM (%)
Frequency in relation to the 
total number of device studies 
(%)
EQ-5D 29.7 6.2
VAS 19.7 4.1
SF-36 6.6 1.4
SF-12 2.6 0.5
PSI 1.0 0.2
NRS 0.3 0.1
Total 59.9 12.5
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because not all device studies are conducted for regulatory 
purposes.
For CE marking, the acceptability of a medical device is 
based on comparison to existing alternatives. To avoid pre-
market clinical studies, manufacturers often claim equiva-
lence with CE-marked devices that are already in clinical 
use. This has kept the regulatory barrier low for medical 
devices, in comparison with the relatively high regulatory 
barriers for drugs. Pre-market clinical investigations are 
required for the CE marking of implantable and high-risk 
medical devices of new design.
The increasing number of device studies and the inclu-
sion of PROMs may be attributed to the recent EU direc-
tive (Directive 2014/24/EU) on public procurement. Public 
Table 4  Frequency of general and disease-specific PROMs in device studies
In the first column, the general health-related quality-of-life (HRQoL) measures are set out. In the brackets, the first value expressed in per-
centage indicates the frequency of PROMs in relation to the total number of studies in the concerned device category. The second percentage 
indicates the frequency of the PROM concerned relative to the number of studies that included PROMs. In the second column, the frequency of 
disease-specific PROMs is indicated according to the same methodology. The third column indicates the proportion of HRQoL measures relative 
to the total number of studies (upper value) and to the overall number of studies that included PROMs in the concerned device category. Values 
close to 0 indicate rare use of general HRQoL measures in the studies, while values close to 1 mean most of the studies included at least one of 
measure. Values over 1 means that studies included more than one general HRQoL measures in average. The use of general HRQoL measures 
was the highest in clinical studies of spinal fusion devices, orthopedic plates, and bone grafts, respectively
EQ-5D EuroQol-5-dimensions, VAS visual analogue scale, SF-08/36/12 short form 36/12, MLWHF Minnesota Living with Heart Failure, ODI 
Oswestry disability index, HHS Harris hip score, OHS Oxford hip score, WOMAC Western Ontario and McMaster universities osteoarthritis 
index, HOOS hip disability and osteoarthritis outcome score, VFQ-25 visual functioning questionnaire, NRS numeric-rating scale, CLUE contact 
lens user experience, PSI patient satisfaction index, DASH disabilities of the arm, shoulder and hand, OHIP oral health impact profile, PRWE 
patient-rated wrist evaluation
Device categories Frequency of general HRQoL meas-
ures (% of total studies/% of studies 
with PROM)
Frequency of disease-specific 
PROMs (% of total studies/in % of 
studies with PROM)
Proportion of general HRQoL meas-
ures (to the total number of studies/to 
studies with PROM)
Absorbable sutures VAS (2%/17%) – NA
Bone grafts VAS (7%/48%)
EQ-5D (3%/21%)
SF-36 (2%/12%)
SF-12 (2%/12%)
ODI (1%/9%) 0.1
0.9
Cardiac pacemakers EQ-5D (2%/12%)
SF-36 (2%/16%)
VAS (1%/10%)
MLWHF (3%/20%) 0.06
0,4
Central venous catheters SF-36 (1%/20%)
VAS (1%/20%)
EQ-5D (0.5%/10%)
QLQC30 (1%/20%)
VAD (0.5%/10%)
QASICC (0.5%/10%)
0.3
0.5
Contact lens solutions VAS (3%/11%) CLUE (1%/11%)
VFQ25 (1%/11%)
0.025
0.1
Dental implants VAS (2.5%/25%) OHIP-14 (1%/10%)
OHIP-15 (0.5%/5%)
OHIP-G-49 (0.5%/5%)
0.05
0.25
Hip implants EQ-5D (21%/46%) HHS (28%/63%)
OHS (18%/40%)
WOMAC (7%/15%)
HOOS (7%/15%)
0.2
0.5
Intramedullary nails EQ-5D (16%/38%)
VAS (8%/19%)
HHS (8%/19%)
DASH (8%/19%)
0.25
0.6
Intraocular lens EQ-5D (1%/6%)
VAS (1%/6%)
VF-14 (2%/15%)
VFQ25 (2%/12%)
0.02
0.1
Orthopedic plates EQ-5D (35%/72%)
VAS (12%/24%)
SF-12 (4%/9%)
DASH (11%/22%)
PRWE (6%/13%)
0.5
1.1
Peripheral venous catheters VAS (3%/67%)
NRS (2%/33%)
– NA
Spinal fusion devices VAS (23%/67%)
SF-36 (10%/28%)
EQ-5D (9%/11%)
PSI (4%/6%)
ODI (21%/31%) 0.4
1.4
S139Is the trend of increasing use of patient-reported outcome measures in medical device studies…
1 3
procurement is the acquisition of goods and services on 
behalf of a public authority or other body, such as hospital 
or other healthcare provider. In the EU, a large fraction of 
medical devices is purchased through public procurement, 
including consumable and implantable devices [16]. The 
public procurements are increasingly relying on auction 
mechanism, which starts with the publication of the require-
ments of the contracting body. Expressions of interest then 
are invited from potential tenderers [17]. The second step 
involves the invitation to pre-selected tenderers who have 
the requisite level of professional, technical, and financial 
expertise and capacity. The submitted tenders are evaluated 
according to their compliance with the published award cri-
teria that may be either the lowest price or the most econom-
ically advantageous tender (MEAT). The lowest price evalu-
ation method is the most transparent, but quality may only be 
taken into account to the extent of the upfront fixed technical 
specification. The MEAT method allows the evaluation of 
both price and quality, including technical merits and func-
tional characteristics, which requires technical competence 
on the part of the tenderer [18]. The public procurement of 
medical technologies is often decentralized at hospital level, 
because only the end-user clinicians are able to evaluate the 
possible clinical outcome of a device.
The new regulatory framework was meant to shift pro-
curement from the lowest price approach towards a value-
based approach by encouraging public authorities to put 
more emphasis on quality, life-cycle costing, cost effec-
tiveness, and societal benefits. A recent report shows that 
Sweden, the United Kingdom, Germany, Spain, France, 
Switzerland, Italy, and The Netherlands have incorporated 
the directive into their own national law. Six core catego-
ries of medical devices are moving towards value-based 
procurement, albeit at different speeds. The report suggests 
that orthopedics and cardiology are expected to be the most 
advanced in the transition over the next few years [19]. Our 
results support this assumption as trauma and orthopedic 
device studies included PROMs the most often, though this 
does not hold completely true for cardiologic devices. Based 
on these findings, we speculate that the growth in use of 
PROMs has been localized in countries that have started 
to shift their public procurement from price towards value-
based (price and quality) approach [20]. For commodity 
products, such as absorbable sutures, catheters, and contact 
lens solutions, price may remain the most important procure-
ment criterion. Our results coincide with this assumption as 
well, since PROMs were considerably less often included 
in studies of these device categories. In conclusion, the 
trend of volunteer inclusion of PROMs in clinical studies 
of some particular medical devices, which are used in the 
most expensive and risky service lines may be a sign of the 
increasing demand by purchasers for the demonstration of 
safety and performance in addition to price.
The results of our study should be interpreted in light 
of its limitations. Since information listed in clinical trial 
registries relies on study sponsors, we cannot be certain that 
the data are current and accurate. Not all device studies may 
have been registered in the searched databases. The limita-
tion of our research to 12 device groups limits generaliz-
ability. For instance, cardiologic devices were supposed to 
include PROMs in comparable quantity to trauma and ortho-
pedic device studies. The random selection of only a few car-
diologic devices could cause selection bias that reduces the 
reliability of the results. The variability of applied PROMs 
concerning the various device categories may arise from the 
disparity in the existence of suitable instruments.
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